Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β -Thalassaemia Patients with Chronic Iron Overload: A UK Perspective

Anthony Bentley · Samantha Gillard ·
Michael Spino · John Connelly · Fernando Tricta

Published online: 5 November 2013
© Springer International Publishing Switzerland 2013

Erratum to: *PharmacoEconomics* (2013) 31:807–822 DOI 10.1007/s40273-013-0076-z

After publication it was identified by the authors that they had supplied the incorrect figure files for Fig. 2a–c (located on p. 817). Attached to this erratum are the correct files. In addition, there is some additional text to the legend of Fig. 2 to be added to the end of the current legend:

*Values truncated for display purposes.

Fig. 2 Tornado diagrams for the sensitivity analyses of DFP vs **a** DFX, **b** DFO, and **c** combination therapy. *BI* balloon infuser, *DFO* desferrioxamine, *DFP* deferiprone, *DFX* deferasirox, *NYHA* New York Heart Association, *Tx* treatment. *Values truncated for display purposes

The online version of the original article can be found under doi:[10.1007/s40273-013-0076-z](https://doi.org/10.1007/s40273-013-0076-z).

A. Bentley (✉) · S. Gillard
Abacus International, 6 Talisman Business Centre,
Talisman Road, Bicester, Oxfordshire OX26 6HR, UK
e-mail: abentley@abacusint.com;
anthony.bentley@abacusint.com

M. Spino · J. Connelly · F. Tricta
ApoPharma Inc., 200 Barmac Drive, Toronto M9L 2Z7, Canada

M. Spino
Leslie Dan Faculty of Pharmacy, University of Toronto,
Toronto, Canada